Search

Dronedarone

[T28] Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. … Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management.

Melphalan

[L40928] It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. … [A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma.[L40928] It is also used for high-conditioning before hematopoietic stem cell transplant.

Aminophylline

The majority of aminophylline medications are discontinued and the remaining medications on the market are in short supply. … Aminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio.

Aluminium phosphate

Magnesium gluconate

Magnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an ingredient in some medicines (such as antacids … In addition, it has been studied for its effects on premature uterine contractions [A32808].

Amifostine

A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.

Relugolix

[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022.[L42150] Relugolix has also been studied in the symptomatic treatment of endometriosis. … It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and more recently by the United States' FDA in 2020, under the brand name

Oxethazaine

Oxetacaine, also called oxethazaince, is a potent surface analgesic with the molecular formula N, N-bis-(N-methyl-N-phenyl-t-butyl-acetamide)-beta-hydroxyethylamine that conserves its unionized form at … [A33104] Oxetacaine is approved by Health Canada since 1995 for its use as an antacid combination in over-the-counter preparations.

Betibeglogene autotemcel

Betibeglogene autotemcel is an autologous gene therapy that adds functional copies of the β-globin gene (β^A-T87Q-globin) to hematopoietic stem cells in order to treat β-thalassemia. … [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia

Enoximone

It is used in patients with congestive heart failure. Trials were halted in the U.S., but the drug is used in various countries. … Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption.